Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.

(more…)